Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company is known for its innovative approach combining neuroscience and clinical research to address conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Amylyx's leading product candidate, AMX0035, is designed to potentially slow disease progression and improve patient quality of life.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 2, 2018 | $0.42 | 2018-03-28 | 2018-03-29 |
| January 2, 2018 | $0.36 | 2017-12-28 | 2017-12-29 |
| October 2, 2017 | $0.24 | 2017-09-28 | 2017-09-29 |
Dividends Summary
- Amylyx Pharmaceuticals, Inc. Common Stock has issued 3 dividend payments over the past 1 years
- The most recent dividend was paid 2760 days ago, on April 2, 2018
- The highest dividend payed out to investors during this period was $0.42 per share
- The average dividend paid during this period was $0.34 per share.
Company News
Antisense oligonucleotide (ASO) therapeutics are emerging as a promising treatment approach for rare genetic and neuromuscular disorders, with over 70 pharmaceutical companies actively developing 90+ pipeline therapeutics targeting specific genetic mechanisms.
Amylyx Pharmaceuticals' stock rose over 10% this week after the company reported positive results from a phase 2 clinical trial of its drug AMX0035 for the rare genetic disorder Wolfram Syndrome. The treatment was well-tolerated and showed sustained improvement in pancreatic function, leading the company to plan discussions with the FDA about adv...
Amylyx Pharma (NASDAQ:AMLX) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent So...
Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?